April 13, 2023 05:14 PM EDTUpdated 07:07 PM
Pharma
FDA+

FDA re­jects Lil­ly's ul­cer­a­tive col­i­tis drug mirik­izum­ab over man­u­fac­tur­ing is­sues

Drew Armstrong

Executive Editor

US reg­u­la­tors de­clined to ap­prove Eli Lil­ly’s ul­cer­a­tive col­i­tis drug mirik­izum­ab, the com­pa­ny said, cit­ing man­u­fac­tur­ing is­sues.

Mirik­izum­ab is an an­ti­body …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times